MENLO PARK, Calif. - Pacific Biosciences (NASDAQ:PACB), a $324.66 million market cap company trading near its 52-week low, has announced a licensing agreement with The Chinese University of Hong Kong ...
PacBio, a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top ...
MENLO PARK, Calif. - PacBio (NASDAQ:PACB), a $384 million market cap biotechnology company with annual revenue of $156 million, announced Wednesday that EpiCypher has joined its Compatible program, ...
PacBio (NASDAQ: PACB) has announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio’s celebrated HiFi sequencing technology. Revio is ...
CD Genomics, a leading provider of genomic services, is excited to announce the launch of its PacBio Single Molecule, Real-Time (SMRT) Sequencing service. This cutting-edge technology is set to ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026 ...
MENLO PARK, Calif. and WOBURN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer ...
StockStory.org on MSN
PacBio (PACB) Q1 earnings report preview: What to look for
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting earnings this Thursday after market hours.
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results